Omeprazole Bristol Laboratories

Omeprazole, the active ingredient in Omeprazole Bristol Laboratories, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children.

GNH USA supplies Omeprazole Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development in high‑risk patients.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional and mild. - Abdominal pain: mild discomfort. - Flatulence: occasional gas buildup. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Hypomagnesemia: low serum magnesium levels. - Vitamin B12 deficiency: long‑term use may impair absorption. - Acute interstitial nephritis: inflammation of kidney tissue. - Stevens‑Johnson syndrome: rare severe skin reaction. - Bone fractures: increased risk with prolonged therapy.

When using Omeprazole, consider the following safety measures:

- Assess renal function: adjust use in severe impairment. - Evaluate hepatic function: use with caution in liver disease. - Monitor long‑term use: assess need for continued therapy after several months. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Pregnancy and lactation: weigh benefits against potential risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral exposure, may lead to treatment failure. - Dasatinib: lowered plasma levels, reducing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, require more frequent monitoring. - Phenytoin: decreased serum levels, may need dose adjustment. - Ketoconazole: reduced absorption, consider alternative antifungal. - Digoxin: modest increase in serum concentration, monitor for toxicity.